Dosage & Reconstitution Guide
Retatrutide Dosage & Reconstitution Guide
A clear educational guide covering Retatrutide reconstitution, unit conversions, gradual protocol examples, supplies, storage, injection technique, clinical research notes and safety considerations.
Quickstart Highlights
- Peptide: Retatrutide
- Common vial size: 10mg
- Example reconstitution: 1.0mL bacteriostatic water
- Resulting concentration: approximately 10mg/mL
- U-100 syringe maths: 1 unit = 0.01mL = approximately 100mcg
- Common research range discussed: 2mg to 8mg once weekly
- Advanced research range discussed: up to 12mg once weekly in Phase 2 trial contexts
- Storage after mixing: refrigerate at 2-8°C and use within around 4 weeks
What is Retatrutide?
Retatrutide is an investigational triple-receptor agonist peptide. It targets GLP-1, GIP and glucagon receptors, which is why it is often discussed separately from single or dual incretin compounds.
In clinical research, Retatrutide has been studied for obesity and type 2 diabetes. The source protocol notes Phase 2 trial results showing substantial weight-loss outcomes at higher weekly doses, with gradual titration used to reduce gastrointestinal side effects.
Retatrutide Reconstitution Example
The example below is based on a common 10mg Retatrutide vial mixed with 1.0mL bacteriostatic water.
Reconstitution Maths
10mg ÷ 1.0mL = 10mg/mL
10mg/mL = 10,000mcg/mL
1 unit on a U-100 syringe = 0.01mL
10,000mcg/mL × 0.01mL = approximately 100mcg per unit
Retatrutide Unit Conversion Table
Standard Gradual Research Example
Advanced Research Example
The source protocol also includes a more aggressive research-style example where the weekly amount increases to 12mg after week 13. This reflects higher-dose Phase 2 trial contexts and should be handled very carefully.
Frequency and Timing Notes
Retatrutide is commonly discussed as a once-weekly subcutaneous compound in clinical trial contexts. The source protocol uses 4-week escalation steps to reduce gastrointestinal side effects.
Timing is usually flexible. The practical point is to use the same day each week, track the weekly amount, and rotate injection sites.
Reconstitution Steps
- Confirm the vial size before calculating concentration.
- Draw 1.0mL bacteriostatic water using sterile technique.
- Inject slowly down the inside wall of the vial.
- Avoid blasting the powder directly and avoid creating foam.
- Gently swirl or roll the vial until dissolved.
- Do not shake vigorously.
- Label the vial with the reconstitution date and concentration.
- Store refrigerated at 2-8°C, protected from light.
- Use within around 4 weeks after reconstitution.
Supplies Needed
Retatrutide Vials
- 12-week standard example to 6mg: approximately 5 × 10mg vials.
- 24-week standard example to 8mg: approximately 15 × 10mg vials.
- 12-week aggressive example to 8mg: approximately 6 × 10mg vials.
Insulin Syringes
- Weekly example: 1-2 syringes per week depending on dose and whether splitting volume is required.
- 12 weeks: approximately 12-24 syringes.
- 24 weeks: approximately 24-48 syringes.
Bacteriostatic Water
- Per 10mg vial: 1.0mL bacteriostatic water.
- 12-week example: 5 vials × 1.0mL = 5mL total, so 1 × 10mL bottle is usually enough.
- 24-week example: 15 vials × 1.0mL = 15mL total, so 2 × 10mL bottles may be needed.
Alcohol Swabs
- Per administration: one swab for the vial stopper and one for each injection site.
- Per week: approximately 2-4 swabs depending on whether the dose is split.
- 12 weeks: around 50 swabs, so 1 × 100-count box is usually enough.
- 24 weeks: around 100 swabs, so 1 × 100-count box is usually enough.
Protocol Overview
- Goal discussed in research: weight reduction and metabolic improvements through triple-receptor activation.
- Schedule example: once-weekly subcutaneous administration.
- Common research range: 2-8mg weekly in standard examples.
- Advanced research range: up to 12mg weekly in higher-dose Phase 2 contexts.
- Titration: gradual 4-week escalation steps are commonly discussed.
- Example reconstitution: 1.0mL bacteriostatic water per 10mg vial.
- Concentration: approximately 10mg/mL.
- Storage: lyophilised frozen, reconstituted refrigerated and used within around 4 weeks.
Example Dosing Protocol
- Start: 2mg weekly for 4 weeks to assess tolerance.
- Escalation: increase by 2-4mg every 4 weeks as tolerated.
- Standard target example: 6-8mg weekly.
- Advanced target example: 12mg weekly in higher-dose research contexts.
- Frequency: once weekly, same day each week.
- Practical note: doses above 10mg may require more than one vial and may need splitting into separate injection sites.
How Retatrutide Works
Retatrutide is designed to activate GLP-1, GIP and glucagon receptors. GLP-1 and GIP receptor activity are linked with insulin secretion when glucose is present, appetite regulation and satiety.
The additional glucagon receptor activity is discussed as increasing energy expenditure and supporting lipid oxidation, which may contribute to the larger weight-loss effects seen in clinical research compared with single-receptor approaches.
The source protocol notes that Retatrutide has a fatty-acid modification that extends circulation time, supporting once-weekly dosing.
Potential Benefits Discussed in Clinical Research
- Substantial weight-loss outcomes in Phase 2 obesity research
- Improved glycaemic control in type 2 diabetes research
- HbA1c reduction discussions
- Waist circumference reduction
- Blood pressure and lipid marker improvements
- Liver fat and hepatic steatosis research contexts
- Increased satiety and reduced calorie intake discussions
- Energy expenditure and lipid oxidation pathways
Reported Side Effects and Limitations
- Nausea
- Vomiting
- Diarrhoea
- Gastrointestinal discomfort, especially during dose escalation
- Dose-dependent and transient side effects reported in trial contexts
- Possible dehydration risk if gastrointestinal symptoms occur
- Not FDA-approved and still investigational
- Unknown long-term outcomes outside clinical trial settings
Storage Instructions
- Lyophilised powder: store frozen at around -20°C or colder in dry, dark conditions.
- After reconstitution: refrigerate at 2-8°C.
- Use window: commonly discussed as within approximately 4 weeks after reconstitution.
- Protect from light: keep the vial away from unnecessary light exposure.
- Avoid: heat, moisture, contamination and repeated freeze-thaw cycles.
- Practical note: allow vials to reach room temperature before opening to reduce condensation.
Injection Technique Notes
This section is general educational information only. It is not personal injection instruction.
- Use a new sterile insulin syringe for each administration.
- Clean the vial stopper and injection site with alcohol and allow both to dry completely.
- Common subcutaneous sites discussed include abdomen, thighs and upper arms.
- Rotate injection sites systematically to reduce local irritation and lipohypertrophy risk.
- Pinch a skinfold and insert into subcutaneous tissue at an appropriate angle.
- Do not aspirate for subcutaneous injections.
- Inject slowly and steadily.
- Wait a few seconds before withdrawing the needle to support full dose delivery.
- For volumes above 1.0mL, the source protocol discusses splitting into two injections at separate sites.
- Dispose of used sharps safely in a sharps container.
Lifestyle Factors That May Matter
- Protein-forward diet: adequate protein may help support lean mass during weight-loss research contexts.
- Resistance training: training 2-3 times weekly is commonly discussed to help preserve muscle.
- Aerobic activity: regular cardio may support metabolic adaptation.
- Sleep: 7-9 hours supports adherence, appetite control and hormonal balance.
- Hydration: important if nausea, vomiting or diarrhoea occurs.
- Metabolic markers: HbA1c, lipids and liver markers are commonly discussed in clinical research monitoring.
Use the Peptide Calculator
If your vial size, water volume or target amount is different, use the Peptide Hub Australia calculator to work out concentration, mL and syringe units.
Calculate Retatrutide Units
Enter your vial size, BAC water amount and target amount to calculate concentration and syringe units.
Open Peptide CalculatorWhere to Compare Retatrutide Suppliers
Peptide Hub Australia does not sell Retatrutide or any other peptides. We compare Australian peptide vendors, package audits, pricing and supplier information to help users review the market more clearly.
Frequently Asked Questions
How much BAC water do you add to a 10mg Retatrutide vial?
A common educational example is 1.0mL bacteriostatic water added to a 10mg vial, creating a concentration of approximately 10mg/mL.
How many units is 2mg of Retatrutide?
If a 10mg vial is mixed with 1.0mL, 2mg is approximately 20 units on a U-100 insulin syringe, equal to around 0.20mL.
How many units is 4mg of Retatrutide?
If a 10mg vial is mixed with 1.0mL, 4mg is approximately 40 units on a U-100 insulin syringe, equal to around 0.40mL.
How many units is 8mg of Retatrutide?
If a 10mg vial is mixed with 1.0mL, 8mg is approximately 80 units on a U-100 insulin syringe, equal to around 0.80mL.
How many units is 12mg of Retatrutide?
At 10mg/mL, 12mg equals approximately 120 units, or 1.20mL. This may require more than one vial and may need splitting into separate injection sites in research-style handling discussions.
How long does one 10mg Retatrutide vial last?
At 2mg weekly, one vial contains around 5 weekly administrations. At 4mg weekly, it contains around 2.5 administrations. At 8mg weekly, it contains slightly more than one administration.
Is Retatrutide approved?
No. The source protocol notes that Retatrutide is investigational and not FDA-approved.
What makes Retatrutide different from GLP-1 only compounds?
Retatrutide targets three receptor pathways: GLP-1, GIP and glucagon. The glucagon receptor activity is discussed as supporting energy expenditure and lipid oxidation.
Is this a personal dosing recommendation?
No. This page is an educational reconstitution and measurement guide only. It is not medical advice or a personal protocol.
